HC Wainwright Has Positive Estimate for MAZE Q3 Earnings

Maze Therapeutics, Inc. (NASDAQ:MAZE) – Equities researchers at HC Wainwright increased their Q3 2026 earnings per share estimates for Maze Therapeutics in a research report issued on Wednesday, August 12th. HC Wainwright analyst A. Ghosh now anticipates that the company will post earnings of ($0.77) per share for the quarter, up from their prior estimate of ($0.87). The consensus estimate for Maze Therapeutics’ current full-year earnings is ($2.73) per share. HC Wainwright also issued estimates for Maze Therapeutics’ Q4 2026 earnings at ($0.80) EPS, FY2026 earnings at ($2.81) EPS, FY2027 earnings at ($3.27) EPS, FY2028 earnings at ($2.89) EPS, FY2029 earnings at ($2.46) EPS and FY2030 earnings at ($0.72) EPS.

Maze Therapeutics (NASDAQ:MAZE) last announced its earnings results on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, meeting the consensus estimate of ($0.76).

Other analysts have also issued research reports about the stock. Wall Street Zen raised shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. BTIG Research reaffirmed a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a report on Wednesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Maze Therapeutics has an average rating of “Buy” and a consensus price target of $66.00.

Maze Therapeutics Stock Performance

Shares of Maze Therapeutics stock opened at $27.67 on Friday. Maze Therapeutics has a 12 month low of $12.81 and a 12 month high of $53.65. The firm has a market capitalization of $1.54 billion, a P/E ratio of -10.98 and a beta of 2.21. The business’s fifty day simple moving average is $27.73 and its 200 day simple moving average is $33.08. The company has a current ratio of 17.88, a quick ratio of 17.88 and a debt-to-equity ratio of 0.11.

Insiders Place Their Bets

In other news, insider Atul Dandekar sold 7,500 shares of the business’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $27.34, for a total transaction of $205,050.00. Following the sale, the insider owned 26,250 shares in the company, valued at approximately $717,675. The trade was a 22.22% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 14,609 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $29.90, for a total value of $436,809.10. Following the completion of the transaction, the chief marketing officer directly owned 14,609 shares in the company, valued at approximately $436,809.10. This represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 124,532 shares of company stock worth $3,459,026. 5.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Maze Therapeutics

Several institutional investors have recently bought and sold shares of MAZE. Mass General Brigham Inc purchased a new stake in shares of Maze Therapeutics in the 4th quarter valued at $9,943,000. Boothbay Fund Management LLC increased its stake in shares of Maze Therapeutics by 16.3% in the 4th quarter. Boothbay Fund Management LLC now owns 409,372 shares of the company’s stock valued at $16,960,000 after purchasing an additional 57,497 shares in the last quarter. Spruce Street Capital LP acquired a new position in shares of Maze Therapeutics during the 1st quarter worth approximately $5,970,000. Eventide Asset Management LLC purchased a new position in Maze Therapeutics during the fourth quarter valued at $13,425,000. Finally, Exome Asset Management LLC purchased a new position in Maze Therapeutics in the 1st quarter valued at about $2,642,000.

Key Headlines Impacting Maze Therapeutics

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: HC Wainwright reduced several projected losses. The firm raised its EPS forecasts for Q3 2026 to $(0.77) from $(0.87), Q4 2026 to $(0.80) from $(0.82), FY2026 to $(2.81) from $(2.96), FY2027 to $(3.27) from $(3.51), FY2028 to $(2.89) from $(3.08), FY2029 to $(2.46) from $(2.60), and FY2030 to $(0.72) from $(0.74). The revisions suggest expectations for a somewhat narrower cash-burn profile, although the FY2026 forecast remains below the $(2.73) consensus estimate. HC Wainwright earnings estimates
• Positive Sentiment: BTIG Research initiated or reaffirmed a Buy rating on MAZE. The favorable analyst stance adds to the bullish research coverage around Maze’s precision-medicine pipeline. Maze Therapeutics Earns Buy Rating from BTIG Research
• Positive Sentiment: Maze strengthened its board with two experienced healthcare executives. Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., bring clinical, pharmaceutical, partnering, and commercialization expertise. Management also highlighted additional MZE829 data in late 2026 or early 2027, initial MZE782 data in 2027, and additional trial starts next year. Maze Therapeutics Announces Appointments to Its Board of Directors
• Neutral Sentiment: Second-quarter results met expectations. Maze previously reported quarterly EPS of $(0.76), in line with analysts’ consensus. The company’s valuation remains dependent primarily on clinical progress from MZE829 and MZE782 rather than current earnings. Maze Therapeutics Reports Second Quarter 2026 Financial Results
• Negative Sentiment: Insider trading has been heavily weighted toward selling. Reported activity shows 37 insider sales and no purchases over the past six months, potentially limiting bullish sentiment even as institutional ownership activity has been mixed.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.